Dr. Blanchard is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Lilly Corporate Ctr
Bldg 48/2
Indianapolis, IN 46285Phone+1 317-651-9993- Is this information wrong?
Education & Training
- Indiana University School of MedicineClass of 1985
Certifications & Licensure
- IN State Medical License 2000 - 2025
- American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 17 citationsA Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor ModelsXiang S. Ye, Li Fan, Robert D. Van Horn, Ryuichiro Nakai, Yoshihisa Ohta, Shiro Akinaga, Chikara Murakata, Yoshinori Yamashita, Tinggui Yin, Kelly M. Credille, Gregory...> ;Molecular Cancer Therapeutics. 2015 Aug 24
- 57 citationsCdk1 Activity Is Required for Mitotic Activation of Aurora A during G2/M Transition of Human CellsRobert D. Van Horn, Shaoyou Chu, Li Fan, Tinggui Yin, Jian Du, Richard P. Beckmann, Mary M. Mader, Guoxin Zhu, John E. Toth, Kerry L. Blanchard, Xiang S. Ye> ;The Journal of Biological Chemistry. 2010 Jul 9
- 294 citationsTherapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicityJeremy R. Graff, Bruce W. Konicek, Thomas M. Vincent, Rebecca L. Lynch, David Monteith, Spring Weir, Phil Schwier, Andrew Capen, Robin L. Goode, Michele Dowless, Yuefe...> ;The Journal of Clinical Investigation. 2007 Sep 4
- Join now to see all
Press Mentions
- Gilead to Acquire Remaining Worldwide Rights of Trodelvy®August 15th, 2022
- Everest Medicines Announces Approval of Trodelvy® in China for Second-Line Metastatic Triple-Negative Breast CancerJune 10th, 2022
- Everest Medicines' Licensing Partner Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod's Potentially Best-in-Class Profile in Ulcerative ColitisMay 24th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: